Highlights
- •There is high frequency of MetS and its component in Egyptian MS patients.
- •Metabolic syndrome was not a significant factor affecting disability in MS patients.
- •Disease duration, current medication, BMI and dyslipidemia were the independent factors significantly associated with disability in MS patients.
Abstract
Background
There is limited and inconsistent data on metabolic syndrome (MetS) in multiple sclerosis
(MS) patients. The aim of this study was to estimate the frequency of MetS and its
components in MS patients and to evaluate their association with disease disability
in Egyptian MS patients.
Methods
A cross-section study was carried out on 60 patients (19 males and 41 females) with
relapsing remitting MS. All patients were subjected to full general and neurological
examination, laboratory and radiological investigations. Assessment of disease disability
was performed using Expanded Disability Status Scale (EDSS) and MetS was diagnosed
according to National Cholesterol Education Program Adult Treatment Panel Ш (NCEP-ATP
III).
Results
The frequency of MetS in MS patients was 36.7%. Our findings show that 53.3% of MS
patients had abdominal obesity, 21.7% had hypertension, 38.3% had diabetes mellitus,
43.3% had elevated triglycerides level and 56.7% had dyslipidemia. Linear regression
analysis revealed that body mass index (BMI), dyslipidemia, current medication and disease duration
were significantly associated with disease disability.
Conclusion
High frequency of MetS and its component was observed in MS patients. Disease duration
and current medication as well as some MetS component such as BMI, dyslipidemia, were
significantly associated with disability in MS patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Obesity and brain inflammation: a focus on multiple sclerosis.Obesity Reviews. 2016; 17: 211-224
- Metabolic syndrome; definitions and controversies.BMC Med. 2011; 9: 48
- Obesity in autoimmune diseases: not a passive bystander.Autoimmun Rev. 2014; 13: 981-1000
- Body size and risk of MS in two cohorts of US women.Neurology. 2009; 73: 1543-1550
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria.Ann. Neurol. 2011; 69: 292-302
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001; 285: 2486-2497
- Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain.BMC Neurol. 2017; 17: 134
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452
- Changes in disability in people with multiple sclerosis: a 10-year prospective study.J. Neurol. 2018; 265: 119-126
- IBM SPSS Statistics for Windows, Version 20.IBM Corp, Armonk, NY2010
- Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability.Eur. J. Neurol. 2015; 22: 1275-1279
- Metabolic Syndrome and Disability in Multiple Sclerosis: a Retrospective Study.Neurology. 2014; 82 (168): P6
- Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis.Egypt J. Neurol. Psychiatry Neurosurg. 2020; 56: 18
- The Metabolic Syndrome in Multiple Sclerosis Patients.N. Y. Sci. J. 2020; 13: 40-47
- Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis.J. Neuroinflammation. 2011; 8: 127
- Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression.Clin. Lipidol. 2014; 9: 473-475
- A population based cohort study suggests an increased risk of multiple sclerosis incidence in patients with type 2 diabetes mellitus.J. Epidemiol. 2017; 27: 235-241
- Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia.Mult. Scler. 2012; 18: 1310-1319
- Metabolomic signatures associated with disease severity in multiple sclerosis.Neurol. Neuroimmunol Neuroinflamm. 2017; 4: e321
- Sedentary Behavior and Blood Pressure in Patients with Multiple Sclerosis.Int. J. MS Care. 2018; 20: 1-8
- Vitamin D and body mass index in Egyptian multiple sclerosis patients.Mult Scler Relat Dis. 2019; 28: 313-316
- Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.Brain. 2008; 131: 808-817
- Infratentorial Lesions Predict Long-term Disability in Patients with Initial Findings Suggestive of Multiple Sclerosis.Arch. Neurol. 2004; 61: 217-221
- Body mass index influence interferon-beta treatment response inmultiple sclerosis.J. Neuroimmunol. 2015; 288: 92-97
- Prognostic factors of disability in relapsing remitting multiple sclerosis.Mult Scler Relat Dis. 2019; 30: 9-16
- Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.Mult Scler. 2017; 23: 277-285
- Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.J Neurol Neurosur Ps. 2013; 84: 1186-1191
- Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.J neurol neurosurg psychiatry. 2014; 85: 859-864
- Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis.Neuroepidemiology. 2016; 46: 106-113
- Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis.Neurology. 2014; 82: 865-872
- Raised interleukin-6 levels in obese patients.Obes. Res. 2000; 8: 673-675
- Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.Neurology. 2013; 80: 548-552
- Body mass index, but not vitamin D status, is associated with brain volume change in MS.Neurology. 2018; 91: e2256-e2264
- Association of pre-disease body mass index with multiple sclerosis prognosis.Front Neurol. 2018; 9: 232
Article info
Publication history
Published online: July 02, 2020
Accepted:
June 23,
2020
Received in revised form:
June 9,
2020
Received:
May 2,
2020
Identification
Copyright
© 2020 Elsevier B.V. All rights reserved.
